REF115081_v2 12/18

REFRESH® REPAIR promotes healing of the cornea and conjunctival epithelia, and improves visual performance in Dry Eye patients.

HELP HEAL YOUR PATIENTS’ DRY EYES.

refreshbrand.com/doc |*HA is an inactive ingredient.

Repairs the eye’s dry, damaged corneal

epithelial cells, restores essential moisture

to the tear film, and coats with a protective

shield to maintain cell health so the ocular

surface can function properly.

REFRESH® REPAIR is clinically proven to treat

the signs and symptoms of Dry Eye while

delivering improved visual performance in

Dry Eye patients.

AND OSMOPROTECTANTS.

FIRST AND ONLYARTIFICIAL TEAR IN THE U.S. WITH CMC, HA,*

Relieve. Restore. Repair.™

Study design: Three-month, multicenter, double-masked, randomized study in patients with Dry Eye Disease (n=305). Patients were assessed at baseline and at all follow-up visits (days 7, 30, 60, and 90). The primary effi cacy variable was the change from baseline in OSDI score at Day 90. The primary effi cacy

analysis was performed for the ITT population using a strategy of combined noninferiority and superiority tests. The primary effi cacy endpoint was met.1

Change in Combined Corneal and Conjunctival Staining

% C

hang

e fr

om B

asel

ine

0%

-5%

-10%

-30%

-15%

-35%

-20%

-25%

Study Days

Day 90

-31%

Day 7

-20%

Study Days

Change in Ocular Surface Disease Index (OSDI)

% C

hang

e fr

om B

asel

ine

0%

-5%

-30%

-10%

-35%

-15%

-40%

-20%

-45%

-25%

Day 7 Day 90

-28%

-40%

REFRESH® REPAIR Helps Promote Healing of the Cornea andConjunctival Epithelia and Signifi cantly Relieves Dry Eye Symptoms1

A visual disturbance questionnaire distributed after patients used REFRESH® REPAIR for seven days revealed that:

Improves Clarity of Vision1

70% of patients reported no blur when the drop was fi rst applied

70% of patients said the thickness of the drop is just right

85% of patients reported no blur after less than fi ve minutes of application

70

85

70

Visual Disturbance QuestionnaireResults at Day 7 (n=101)1

%

%

%

Study design: Three-month, multicenter, double-masked, randomized study in patients with Dry Eye Disease (n=305). Patients were assessed at baseline and at all follow-up visits (days 7, 30, 60, and 90). The primary effi cacy variable was the change from baseline in OSDI score at Day 90. The primary effi cacy analysis

was performed for the ITT population using a strategy of combined noninferiority and superiority tests. The primary effi cacy endpoint was met.1

Signifi cantly Improves Vision-Related Functions,Ocular Symptoms, and Environmental Irritation

(as measured by OSDI scores by visit)1

Study Days

Change in Ocular Symptoms(grittiness, eye pain or soreness, blurred

or poor vision, and light sensitivity)

% C

hang

e fr

om B

asel

ine

0%

-5%

-30%

-10%

-35%

-15%

-40%

-20%

-45%

-25%

Day 7 Day 90

-36%

-22%

Study Days

Change in Vision-related Functions(reading, driving at night, working with

a computer, and watching TV)

% C

hang

e fr

om B

asel

ine

0%

-5%

-30%

-10%

-35%

-15%

-40%

-20%

-45%

-25%

Day 7 Day 90

-35%

-43%

Study Days

Change inEnvironmental Triggers(windiness, air-conditioned areas, and low humidity)

% C

hang

e fr

om B

asel

ine

0%

-5%

-30%

-10%

-35%

-15%

-40%

-20%

-45%

-25%

Day 7 Day 90

-28%

-40%

Extends Tear Breakup Time (TBUT)1

0%

5%

10%

15%

20%

25%

30%

35%

Day 7Baseline Day 90

Mean Change in TBUT (Seconds) from Baseline

Mea

n TB

UT

from

Bas

elin

e

Study design: Three-month, multicenter, double-masked, randomized study in patients with Dry Eye Disease (n=305). Patients were assessed at baseline and at all follow-up visits (days 7, 30, 60, and 90). The primary effi cacy variable was the change from baseline in OSDI score at Day 90. The primary effi cacy

analysis was performed for the ITT population using a strategy of combined noninferiority and superiority tests. The primary effi cacy endpoint was met.1

22%

31%

P<.001

P<.001

THE FACT ABOUT SALT AND ORGANIC OSMOLYTES IN ARTIFICIAL TEARS

50

0

100

150

200

250

300

247

Salt-related Osmolality (mOsm/kg)

(mO

sm/k

g)

254 255

REFRESH® REPAIR and other REFRESH® brand formulas are low in salt and rich in organic osmolytes.

Blink® Tears

108

TheraTears®

47

Clear Eyes®

Pure Relief ™

102

Visine® Tears®

159

Systane® Ultra

187

Organic Osmolyte-related Osmolality (mOsm/kg)

Organic Osmolytes vs. Salt in Artificial Tears2

WHY?A dry eye is a salty eye. In other words, it has a higher tear film osmolarity. Excess salt in the tear film causes

epithelial cells to lose water and volume leading to a higher salt concentration, which if left untreated, can lead to inflammation and cell damage. To restore volume, these salt-stressed cells will take in organic osmolytes.

Water returns to the cell, internal salt levels return to normal, and cell volume is restored.

FACTAll artificial tears have salt, but those low in salt and

rich in organic osmolytes can better protect the eyes against the damage from hyperosmolar tears.

Start selling REFRESH® in your office. Call 1-833-246-4393 to get started today.

Osmoprotection Runs in the FamilyThese advanced formulas from REFRESH® feature Osmoprotectants

that help fight against hyperosmotic stress.

REFRESH® REPAIR

Repairs and ProtectsRepairs the eye’s dry, damaged corneal epithelial cells, restores essential moisture to the tear film, and coats with a protective shield to maintain cell health so the ocular surface can function properly.

REFRESH OPTIVE MEGA-3®

Nourishes and Protects

Formulated with a blend of natural oils, which protects tears from evaporation often caused by MGD while nourishing

the tear film.

REFRESH OPTIVE® GEL DROPSExtended Therapy

Our most comprehensive gel formula, clinically proven to provide prolonged relief from

Dry Eye symptoms, day or night.

REFRESH OPTIVE® ADVANCED Triple-action Relief

Works on all three layers of the tear film and helps lubricate, hydrate, and prevent tears from evaporating.

1. Simmons PA et al. Efficacy and safety of two new formulations of artificial tears in subjects with dry eye disease: a three-month, multicenter, active-controlled, randomized trial. Clinical Ophthalmology. 2015;9:665-667. 2. Liu H et al. Organic Osmolites as Osomotic Agents vs. Salt in Artificial Tears. Poster presented at the 2018 Annual Meeting of the ARVO. April 29–May 3, 2018. Honolulu, HI.

© 2018 Allergan. All rights reserved. All trademarks are the property of their respective owners.